Final Biomarker and Efficacy Analyses of Lorlatinib in Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer in a Phase 2 Study. (PubMed, J Thorac Oncol) - Sep 17, 2026 - "After 5 years of follow-up, final analyses from this phase 2 study further supported substantial activity and prolonged OS with lorlatinib in treatment-naive and previously treated patients with ALK-positive advanced NSCLC, regardless of the biomarker subgroups. Resistance mechanisms in treatment-naive patients did not include emergence of ALK mutations."
Biomarker • Journal • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EML4 • TP53
|
|
Alice T Shaw; Benjamin Besse; Benjamin J Solomon; Chia-Chi Lin; D Ross Camidge; Deborah A Shepard; Enriqueta Felip; Francesca Toffalorio; Gregory J Riely; I-Ming Wang; Jean-François Martini; Phineas Hamilton; Rita Chiari; Ross A Soo; Shirish Gadgeel; Steven Kao; Tiziana Usari; Todd M Bauer
|